Puma Biotechnology Announces Publication Of Phase II Clinical Trial Of Alisertib In JAMA Oncology
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with